Durable and reversible epigenetic programming of human hematopoietic stem cells as a platform for modulation of platelet function
Related Experiment Video
Updated: Nov 7, 2026

Hemogenic Reprogramming of Human Fibroblasts by Enforced Expression of Transcription Factors
Published on: November 4, 2019
Tianyi Ye1, Wanying Xu1, Maria N Barrachina2
1Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA; Howard Hughes Medical Institute, Boston, MA 02115, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Abstract:
Programmable epigenome editing offers control of gene expression without altering DNA sequence, but its capacity to program human hematopoietic stem cells (HSCs) and their differentiated progeny remains incompletely characterized. Here, we establish that DNA methylation-based epigenome editors delivered transiently as RNA induce heritable gene silencing in primary human HSCs. Targeting the platelet integrin β3 (ITGB3) produced silencing that persisted through long-term HSC self-renewal and megakaryocytic differentiation, impaired aggregation of in vitro-derived platelets, and was partially reversed through targeted demethylation at this locus. Silencing remained stable in human HSCs 4 months after transplantation into mice. Targeting additional platelet-associated genes demonstrated broad applicability with this approach. Together, these findings establish DNA methylation-based epigenome editing as a platform for durable and reversible programming of human HSCs and demonstrate its application to modulating platelet function.
Related Concept Videos
Multipotency of Hematopoietic Stem Cells
Regulation of Hematopoietic Stem Cells

